

## The Republic of Tajikistan

### Support for Vaccine: DTP-HepB-Hib

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b>	The Republic of Tajikistan																						
<b>2. Vaccine grant number:</b>	0810-TJK-04a-X; 0708-TJK-03d-X; TJK-NVS-1; TJK-NVS-2; TJK-Lumpsum-1; 08-TJK-08b-Y, 1115-TJK-04A-X, 16-TJK-04a-X, 17-TJK-04a-X, 18-TJK-04a-X, 19-TJK-04a-X, 20-TJK-04a-X																						
<b>3. Date of Decision Letter:</b>	30 September 2019																						
<b>4. Date of the Partnership Framework Agreement:</b>	07 November 2012																						
<b>5. Programme title:</b>	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																						
<b>6. Vaccine type:</b>	DTP-HepB-Hib																						
<b>7. Requested product presentation and formulation of vaccine:</b>	Penta, 1 dose per vial, LIQUID																						
<b>8. Programme Duration:<sup>1</sup></b>	2002-2020																						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement)																						
	<b>2002-2019</b>	<b>2020</b>	<b>Total<sup>2</sup></b>																				
<b>Programme Budget (US\$)</b>	18,459,234	669,500	19,128,734																				
<b>10. Vaccine introduction grant</b>	<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="text-align: center;">Year</th> <th style="text-align: center;">Grant Number</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2002</td> <td style="text-align: center;">TJK-Lumpsum-1</td> <td style="text-align: right;">100,000</td> </tr> <tr> <td style="text-align: center;">2008</td> <td style="text-align: center;">08-TJK-08b-Y</td> <td style="text-align: right;">100,000</td> </tr> </tbody> </table> <table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="text-align: center;">Disbursement date</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">11 February, 2002</td> <td style="text-align: right;">100,000</td> </tr> <tr> <td style="text-align: center;">07 April, 2008</td> <td style="text-align: right;">100,000</td> </tr> </tbody> </table>			Approval			Year	Grant Number	Amount (US\$)	2002	TJK-Lumpsum-1	100,000	2008	08-TJK-08b-Y	100,000	Disbursement		Disbursement date	Amount (US\$)	11 February, 2002	100,000	07 April, 2008	100,000
Approval																							
Year	Grant Number	Amount (US\$)																					
2002	TJK-Lumpsum-1	100,000																					
2008	08-TJK-08b-Y	100,000																					
Disbursement																							
Disbursement date	Amount (US\$)																						
11 February, 2002	100,000																						
07 April, 2008	100,000																						
<b>11. Product switch grant:</b>	Not applicable																						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement)																						
	<b>2002-2019</b>	<b>2020</b>																					
<b>Type of supplies to be purchased with Gavi funds</b>																							
Number of vaccine doses		545,200																					
Annual Amounts (US\$)	18,459,234	669,500																					
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																						
<b>14. Self-procurement:</b>	Not applicable																						
<b>15. Co-financing obligations:</b>																							

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

According to the co-financing policy, the Country falls within the group:

Initial self-financing phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023
Number of vaccine doses	101,400	-	-	-
Number of AD syringes	-	-	-	-
Number of re-constitution syringes	-	-	-	-
Number of safety boxes	-	-	-	-
Value of vaccine doses (US\$)	117,609	-	-	-
<b>Total co-financing payments (US\$) (including freight)</b>	<b>129,500</b>	-	-	-

**16. Operational support for campaigns: Not applicable**

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

**18. Financial clarifications:** Not applicable

**19. Other conditions: Not applicable**

Signed by,

**On behalf of Gavi**



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019